Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Hernández Fernandez de Rojas, D; Ibañez, E; Longhurst, H; Maurer, M; Fabien, V; Aberer, W; Bouillet, L; Zanichelli, A; Caballero, T; IOS Study Group.
Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals.
Int Arch Allergy Immunol. 2015; 167(1):21-28
Doi: 10.1159/000430864
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Aberer Werner
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Icatibant, a selective bradykinin B2 receptor antagonist for the treatment of acute hereditary angio-oedema (HAE) attacks in adults, can be administered by health care professionals (HCPs) or self-administered. This analysis compared characteristics and outcomes of acute HAE attacks treated with self-administered and HCP-administered icatibant in a real-world setting. The Icatibant Outcome Survey (Shire, Zug, Switzerland; NCT01034969) is an international observational study monitoring the safety and effectiveness of icatibant treatment. Descriptive retrospective analyses were performed (February 2008 to December 2012). Icatibant was used in 652 attacks in 170 patients with HAE type I/II. Most icatibant injections were self-administered (431/652, 68.5%). The proportion of self-treated attacks increased over time (40.3% in 2009 vs. 89.7% in 2012). The median time to administration was significantly shorter in self- versus HCP-treated attacks (1.5 vs. 2.4 h; p = 0.016). Earlier treatment (<2 h after onset) was significantly associated with a shorter median time to resolution (2.5 vs. 5.0 h; p = 0.032) and attack duration (3.0 vs. 14.0 h; p < 0.0001), regardless of administration method. Patients self-administered icatibant for attacks of all severities; overall, 34.7% of severe and 30.2% of very severe attacks were HCP treated. Logistic regression analysis did not find use of long-term prophylaxis, attack location or gender to be predictive for self-administration. The proportion of HAE attacks treated with self-administered icatibant increased over time. Patients successfully self-administered icatibant for a wide variety of HAE attacks, demonstrating that icatibant is generally well tolerated and effective for self-administration. Self-administration of icatibant provides a complementary option to HCP administration, enabling optimization of patient care. © 2015 S. Karger AG, Basel.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Angioedemas, Hereditary - drug therapy
- Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
- Anti-Inflammatory Agents, Non-Steroidal - adverse effects
- Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
- Bradykinin - administration & dosage
- Bradykinin - adverse effects
- Bradykinin - analogs & derivatives
- Bradykinin - therapeutic use
- Bradykinin B2 Receptor Antagonists - administration & dosage
- Bradykinin B2 Receptor Antagonists - adverse effects
- Bradykinin B2 Receptor Antagonists - therapeutic use
- Data Collection -
- Female -
- Humans -
- Male -
- Middle Aged -
- Prospective Studies -
- Retrospective Studies -
- Self Administration - adverse effects
- Treatment Outcome -
- Young Adult -
- Find related publications in this database (Keywords)
- Hereditary angio-oedema
- Icatibant
- Oedema
- Self-administration
- Icatibant Outcome Survey
- C1 inhibitor deficiency
- Bradykinin B2 receptor antagonist
- Therapy